Recent News

• 06.05.2026 - Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
• 06.03.2026 - MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
• 05.29.2026 - MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
• 05.29.2026 - MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
• 05.27.2026 - MannKind to Present at Jefferies Global Healthcare Conference
• 05.27.2026 - MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

Recent Filings

• 06.02.2026 - 8-K Current report
• 05.28.2026 - 8-K Current report
• 05.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2026 - 4 Statement of changes in beneficial ownership of securities